Breaking News: Pfizer’s mRNA-based vaccine was found to be more than 90% effective in preventing COVID-19. The preliminary Phase 3 results indicate that the vaccine works and is safe.

Pfizer and their collaborator, BioNTech, announced this morning positive efficacy results from their Phase 3, late-stage study of their potential COVID-19 vaccine.

The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis, according to preliminary information the company received from independent third party evaluators.

The study was very robust covering participants ranging from ages 5 to 85 years young. This may be the most significant medical breakthrough in the past century according to Albert Bourla, Pfizer’s Chairman and CEO.

The results demonstrate that Pfizer’s mRNA-based vaccine can help prevent COVID-19 in the majority of people who receive the two doses, twenty-one (21) days apart. Within seven days of receiving second dose, the vaccine has proven 90% effective and is safe.

This means the world is one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic.

In the fight against COVID-19, a vaccine is a critical part of addressing the global health crisis by decreasing rates of infection, disease and death worldwide.

Pfizer and BioNTech leveraged their decades of scientific expertise and worked together to develop, test and manufacture this breakthrough mRNA vaccine to help prevent COVID-19.

Source: https://www.pfizer.com/news/hot-topics/albert_bourla_discusses_covid_19_vaccine_efficacy_results